- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-K Annual report
- 4.6 Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended
- 10.59 First Amendment to Separation and Release Agreement, Dated March 29, 2023, by and Between 180 Life Sciences Corp. and Quan Vu
- 21.1 List of Subsidiaries
- 23.1 Marcum LLP
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference in the Registration Statement of 180 Life Sciences Corp. (the ‘Company’) on Form S-3 (File No. 333-265416), Post-Effective Amendment No.2 to Registration Statement on Form S-1 on Form S-3 (File No. 333-259209) and Form S-8 (File Nos. 333-259918 and 333-266716) of our report dated March 31, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of 180 Life Sciences Corp. as of December 31, 2022 and 2021 and for each of the two years in the period ended December 31, 2022, which report is included in this Annual Report on Form 10-K of the Company for the year ended December 31,2022.
/s/ Marcum llp
Marcum llp
San Francisco, CA
March 31, 2023